"Immunotherapy, Active" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
| Descriptor ID |
D016233
|
| MeSH Number(s) |
E02.095.465.425.400.530 E05.478.550.600
|
| Concept/Terms |
Immunotherapy, Active- Immunotherapy, Active
- Active Immunotherapy
- Active Immunotherapies
- Immunotherapies, Active
Vaccine Therapy- Vaccine Therapy
- Therapy, Vaccine
- Therapies, Vaccine
- Vaccine Therapies
Immune RNA Manipulation- Immune RNA Manipulation
- Immune RNA Manipulations
- Manipulation, Immune RNA
- Manipulations, Immune RNA
- RNA Manipulation, Immune
- RNA Manipulations, Immune
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Active".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Active".
This graph shows the total number of publications written about "Immunotherapy, Active" by people in this website by year, and whether "Immunotherapy, Active" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Active" by people in Profiles.
-
Intratumoral immunotherapy for melanoma. Cancer Immunol Immunother. 2015 Jul; 64(7):911-21.
-
MAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD mice. Autoimmunity. 2014 Aug; 47(5):341-50.
-
Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy. PLoS One. 2012; 7(9):e45756.
-
Chimeric Trop2 virus-like particles: a potential immunotherapeutic approach against pancreatic cancer. J Immunother. 2011 Apr; 34(3):251-63.
-
Immunotherapy of AML. Cancer Treat Res. 2010; 145:237-55.
-
Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother. 2009 Aug; 58(8):1185-94.
-
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 2008 Feb; 7(2):286-96.
-
Mechanisms of action for an anti-radiation vaccine in reducing the biological impact of high dose and dose-rate, low-linear energy transfer radiation exposure. Radiats Biol Radioecol. 2007 May-Jun; 47(3):286-91.
-
Neutrophil granule proteins as targets of leukemia-specific immune responses. Curr Opin Hematol. 2006 Jan; 13(1):15-20.
-
Early cervical cancer. Curr Treat Options Oncol. 2000 Jun; 1(2):147-55.